📄 pharmacology and toxicology

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

This study develops novel dissymmetric ionizable lipid-based nanoparticles that efficiently deliver ferroptosis-related siRNAs to treat diabetic metabolic disorders and restore islet function in mouse models, offering a safe and potent therapeutic strategy for type 2 diabetes.

Original authors: Zhang, H., Liu, Y., He, F., Xue, G., Kang, Y., Zhang, Z., Ma, J., Xiao, J., Meng, Q.

Published 2026-09-01

📖 3 min read☕ Coffee break read

CC BY 4.0

Original authors: Zhang, H., Liu, Y., He, F., Xue, G., Kang, Y., Zhang, Z., Ma, J., Xiao, J., Meng, Q.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Type 2 diabetes is a condition where the body struggles to manage sugar and fat, leading to high blood sugar levels that can damage organs over time. While current treatments help control symptoms, they often do not stop the underlying disease from progressing. Scientists have long known that a specific type of cell death, driven by a buildup of harmful fats inside cells, plays a major role in damaging the pancreas and liver in diabetic patients. To stop this, researchers are turning to a powerful tool called small interfering RNA, or siRNA. Think of siRNA as a tiny, precise instruction manual that can tell a cell to stop making a specific harmful protein. However, these instructions are fragile and cannot enter cells on their own; they need a protective vehicle to deliver them safely. For years, the best vehicles available have had limitations, often failing to release their cargo effectively or causing unwanted side effects.

In a new study, researchers set out to build a better delivery vehicle from scratch. They were inspired by the way natural cell membranes are built, noting that the fats in our own bodies often have two different tails rather than two identical ones. This asymmetry helps cell membranes bend and fuse, a process essential for life. The team designed and created 34 new types of fat molecules, each with a unique, uneven structure, to see if they could form better delivery packages for siRNA. They mixed these new fats with other standard ingredients to create tiny spheres called lipid nanoparticles. These spheres are designed to protect the fragile genetic instructions as they travel through the bloodstream and then burst open once inside a cell to release their cargo.

The researchers tested these new packages in the lab and found that the ones with the uneven, asymmetrical tails worked significantly better than the current standard. They discovered that the specific shape of the fat tails and the way they were connected mattered greatly. The most successful packages were able to enter cells more easily and, crucially, escape the internal traps that usually destroy them. Once inside, they released their siRNA cargo with much greater efficiency. When the team tested these top-performing packages in mice with diabetes, the results were striking. The mice received injections of the new packages carrying instructions to silence genes involved in that harmful fat buildup. Within weeks, the treated mice showed lower blood sugar levels, less fat accumulation in their livers, and healthier pancreas cells compared to mice treated with the older, standard packages.

The study also looked at how safe these new packages were. The researchers checked the blood and organs of the mice and found no signs of toxicity or damage, suggesting the new materials are gentle enough for use in living animals. By targeting different genes involved in the fat-damage process, the team showed that this delivery method is flexible and could be adapted to treat various aspects of the disease. The work confirms that by mimicking the natural, uneven structure of cell fats, scientists can create much more effective tools for delivering genetic medicine. This approach not only offers a promising new way to treat diabetes by stopping cell damage at its source but also provides a blueprint for designing better delivery systems for other difficult-to-treat diseases.

Technical Summary: Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Problem Statement
Small interfering RNA (siRNA) offers precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation is hindered by the lack of safe and efficient delivery vectors. Naked siRNA is susceptible to nuclease degradation and cannot spontaneously penetrate cell membranes. While Lipid Nanoparticles (LNPs) are the most mature non-viral delivery system, the current clinical benchmark, DLin-MC3-DMA (MC3), exhibits limitations in endosomal escape efficiency, in vivo transfection activity, and adaptability across different gene sequences. Furthermore, Type 2 Diabetes (T2D) remains a major public health challenge with limited curative options; recent evidence suggests ferroptosis (an iron-dependent form of cell death driven by lipid peroxidation) plays a critical role in pancreatic $\beta$ -cell dysfunction and hepatic steatosis in T2D, yet targeted nucleic acid therapies for this pathway are underdeveloped.

Methodology
The study employed a rational design approach inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids (e.g., sphingomyelin), hypothesizing that such structures facilitate the transition of lipid membranes from lamellar to inverted hexagonal phases in acidic endosomes, thereby promoting endosomal escape.

Lipid Synthesis and Screening: The authors designed and synthesized 34 novel ionizable lipids featuring dissymmetric hydrophobic tails. These lipids varied in hydrophilic headgroups (D3, E3, K6, P6), linker chemistries (amine, ester, amide), and hydrophobic tail structures (chain length, unsaturation degree, and number of tails). Two symmetric lipids served as controls.
LNP Formulation and Characterization: The lipids were formulated into LNPs with DSPC, cholesterol, and DMG-PEG2000 (50:38.5:10:1.5 molar ratio). Physicochemical properties (particle size, PDI, zeta potential, encapsulation efficiency, and apparent pKa) were systematically characterized.
In Vitro and In Vivo Screening:
- Cellular Level: Cellular uptake (flow cytometry), gene silencing efficacy (luciferase assay in HepG2-Luc cells), and cytotoxicity (CCK-8 assay) were evaluated. Mechanistic studies utilized confocal microscopy and endocytosis inhibitors to determine uptake pathways and endosomal escape efficiency.
- In Vivo Level: Biodistribution was assessed via Cy5-siRNA imaging in C57BL/6 mice. Safety profiles were evaluated through hemolysis assays, hematology, serum biochemistry, and histopathology in ICR mice.
Therapeutic Validation: Two lead LNPs (O14-LNP and H18a-LNP) were selected to deliver siRNAs targeting ferroptosis-related genes (ALOX12, ACSL4, Keap1) in two T2D models:
- STZ-induced T2D mice (high-fat diet + streptozotocin).
- Spontaneous db/db T2D mice.
  Therapeutic outcomes were measured via glucose/lipid metabolism, islet function (immunofluorescence), hepatic steatosis (Oil Red O/H&E), and ferroptosis pathway modulation (qPCR, immunohistochemistry).

Key Contributions and Results

Structure-Activity Relationships (SAR): The study established that dissymmetric hydrophobic tails significantly enhance delivery performance compared to symmetric controls. Specifically, three-tailed dissymmetric scaffolds, linkers containing both amide and ester bonds, and moderate hydrophobic tail unsaturation were identified as optimal structural motifs.
Identification of Lead Lipids: Two lead formulations, O14-LNP and H18a-LNP, were identified. Compared to MC3-LNP, these candidates demonstrated:
- Superior Physicochemical Properties: Particle sizes in the optimal 90–120 nm range and apparent pKa values (5.8–6.9) conducive to endosomal escape.
- Enhanced Biological Activity: O14-LNP and H18a-LNP showed significantly higher cellular uptake and gene silencing efficiency. Notably, O14-LNP and H18a-LNP achieved an in vivo ED50 for ALOX12 knockdown of 0.08 mg/kg and 0.10 mg/kg, respectively, representing a 41–53% reduction compared to MC3-LNP (0.17 mg/kg).
- Mechanism of Action: Confocal imaging revealed that O14-LNP and H18a-LNP possess superior endosomal escape capacity (lower lysosomal colocalization) compared to MC3. Internalization was primarily mediated by clathrin-mediated endocytosis and macropinocytosis.
Safety Profile: O14-LNP and H18a-LNP exhibited favorable biocompatibility, with cytotoxicity and hemolysis rates comparable to or better than MC3-LNP. In vivo safety studies showed no significant abnormalities in blood parameters, organ function, or histopathology.
Therapeutic Efficacy in T2D:
- In STZ-induced mice, delivery of siALOX12 via O14-LNP and H18a-LNP effectively reversed hyperglycemia, reduced body weight gain, restored the pancreatic $\alpha$ / $\beta$ cell ratio, and alleviated hepatic steatosis.
- In db/db mice, H18a-LNP successfully delivered siRNAs against ACSL4 and Keap1, resulting in dose-dependent improvements in glucose and lipid homeostasis, restoration of GPX4 expression, and reduction of hepatic lipid accumulation.
- The therapeutic mechanism was confirmed as the silencing of pro-ferroptotic genes and the subsequent upregulation of the antioxidant defense molecule GPX4.

Significance
The authors claim this work provides a theoretical foundation for the rational design of novel ionizable lipids by validating the efficacy of dissymmetric hydrophobic tail architectures. The study demonstrates that O14-LNP and H18a-LNP are versatile delivery platforms capable of outperforming the clinical benchmark MC3 in both delivery efficiency and biosafety. Furthermore, the research validates the therapeutic potential of targeting the ferroptosis pathway via siRNA for the treatment of T2D, offering a novel strategy to ameliorate glucose/lipid metabolic disorders and organ damage. The findings support the development of next-generation nucleic acid therapeutics for metabolic diseases.

More like this